Market Overview

Prescribing A Pharmacy Trade: Walgreens Vs. CVS Vs. Fred's

Prescribing A Pharmacy Trade: Walgreens Vs. CVS Vs. Fred's
Related WBA
Vetr Recommends Walgreens As A Strong Buy
Wall Street's M&A Chatter From December 6: DaVita Medical Group, Cleantech-Brighten Holdings, Walgreens-GuoDa
Related RAD
What Wall Street Thinks Of The $69 Billion CVS-Aetna Deal
With Rite Aid Uncertainty Behind It, Could Walgreens Go Shopping?
Stocks to watch next week (Seeking Alpha)

Loop Capital analyst Andrew Wolf recently took an in-depth look at drug store stocks Walgreens Boots Alliance Inc (NASDAQ: WBA), CVS Health Corp (NYSE: CVS) and Fred’s, Inc. (NASDAQ: FRED) and found there is just one stock worth buying in the group.


Loop initiated coverage of Fred’s at Hold with a $6.00 price target. Fred’s is coming off a disappointing 2016, and Wolf says the company has failed to demonstrate that 2017 will be much better.

Fred’s has yet to deliver reliable earnings visibility as its turnaround story has been slow to develop. In the past 18 months, Fred’s has added new management, upgraded pharmacy technology, remodeled 44 stores and taken other steps to improve its supply chain management and update its technology. While Wolf expects these initiatives to improve profitability in the second half of 2017, the turnaround efforts have taken longer than the company originally anticipated.



Loop also initiated coverage of CVS with a Hold rating and $83 price target. Wolf says 2017 was a difficult year for CVS and will likely end up being the first year of declining profits for CVS’s retail business in more than 10 years. In addition, CVS has lost prescription market share to Walgreens and its playbook to return to profitability by focusing on its front-end sales and healthcare marketing is still in its early stages.

Related Link: Mylan Price Target Slashed Even As TLD Drug Receives Tentative Approval


While Wolf doesn’t recommend buying Fred’s or CVS, Loop has initiated coverage of Walgreen’s with a Buy rating and $95 price target. Walgreens is undergoing a transition year in 2017 after the FTC blocked its potential merger with Rite Aid Corporation (NYSE: RAD). However, Wolf says a new series of partnerships and strategic alliances have Walgreen’s positioned to reaccelerate its growth in 2018.

“Going forward, we believe Walgreens’ pharmacy business strategy has been transformed to a high-productivity driven profit model predicated on increasing efficiencies inherent to the ‘productivity loop,’” Wolf wrote.

Despite a broad market rally, the stocks of Walgreens, Fred’s, CVS and Rite Aid are all down year to date.

Latest Ratings for WBA

Dec 2017Deutsche BankInitiates Coverage OnHold
Nov 2017CitigroupMaintainsBuy
Nov 2017Leerink SwannDowngradesOutperformMarket Perform

View More Analyst Ratings for WBA
View the Latest Analyst Ratings

Posted-In: Analyst Color Long Ideas Health Care Price Target Initiation Top Stories Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (FRED + CVS)

View Comments and Join the Discussion!